SMC publishes Collaborative Advice Documents for remdesivir and tixagevimab plus cilgavimab for COVID-19

SMC has published Collaborative Advice Documents for remdesivir and tixagevimab plus cilgavimab for treating COVID-19.  The recommendations are aligned with the NICE guidance for TA971: remdesivir and tixagevimab plus cilgavimab for treating COVID-19.

Remdesivir (Veklury®) is accepted for restricted use in NHSScotland for treating COVID-19 in hospitals in specific patient groups.

Tixagevimab plus cilgavimab (Evusheld®) is not recommended for use in NHSScotland for the treatment of COVID-19 infection.

You can find the NICE final guidance here: Overview | Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | Guidance | NICE